Latest news with #Ranganathan
Glasgow Times
3 days ago
- Entertainment
- Glasgow Times
Romesh Ranganathan to step back from comedy and presenting roles
As well as his successful comedy career, Ranganathan, 47, is also well-known for various presenting roles both on TV and radio. He is host of BBC game show The Weakest Link and also starred in Bafta Award-winning TV series Rob And Romesh Vs, alongside fellow comedian Rob Beckett. Ranganathan has also featured in several BBC documentary series - The Misadventures Of Romesh Ranganathan (BBC Two) and Asian Provocateur (BBC Three). In 2024, he took over Claudia Winkleman's Saturday morning slot on BBC Radio 2 and he also presents Romesh Ranganathan: For The Love Of Hip Hop on the same station. BBC's highest-paid stars (2023/24) Romesh Ranganathan to take a "step back" from career However, Ranganathan, who hails from Crawley, has now revealed he will be "taking a step back" from his career, but emphasised he was not retiring. Speaking to Lauren Laverne on BBC Radio 4's Desert Island Discs, Ranganathan said: "I know that people sort of say I'm busy and I'm always like, trying to work and stuff. "There is no strategy. There's no game plan. I have no end game.
The Herald Scotland
3 days ago
- Entertainment
- The Herald Scotland
Romesh Ranganathan to step back from comedy and presenting roles
He is host of BBC game show The Weakest Link and also starred in Bafta Award-winning TV series Rob And Romesh Vs, alongside fellow comedian Rob Beckett. Ranganathan has also featured in several BBC documentary series - The Misadventures Of Romesh Ranganathan (BBC Two) and Asian Provocateur (BBC Three). In 2024, he took over Claudia Winkleman's Saturday morning slot on BBC Radio 2 and he also presents Romesh Ranganathan: For The Love Of Hip Hop on the same station. BBC's highest-paid stars (2023/24) Romesh Ranganathan to take a "step back" from career However, Ranganathan, who hails from Crawley, has now revealed he will be "taking a step back" from his career, but emphasised he was not retiring. Speaking to Lauren Laverne on BBC Radio 4's Desert Island Discs, Ranganathan said: "I know that people sort of say I'm busy and I'm always like, trying to work and stuff. "There is no strategy. There's no game plan. I have no end game.
Daily Mail
29-04-2025
- Entertainment
- Daily Mail
Comedian Romesh Ranganathan hits out at local council over school 'shambles' after his son offered place on the 'other side of town'
Romesh Ranganathan has criticised his local council after they offered his son a place in a secondary school on the 'other side of town'. The comedian, 47, says he begged West Sussex County Council to look into his youngest child's case after not being offered any of his preferred choices, including the same school as his two elder brothers. A clearly frustrated Mr Ranganathan said he had to ask his local MP to intervene when he received no response, but was later told by the council 'they can't do anything'. The Weakest Link host told the BBC he would be forced to put his son in a taxi when he starts in September to get him to the classroom on time due to the distance between his children's schools. In a post to his Instagram account, Mr Ranganathan described it as a 'shambles' and accused the local authority of 'no longer giving a s**t' in giving priority to children who have siblings at a school. 'So the school that we put down that is the same as his brothers, they've [the council] said you are not having that,' he said. 'Not only you're not having that, you're not having any of the schools you put down as a preference. In fact, we placed you at a school the other side of town. That's it. So I'm like, well no. I don't want that.' He said he had sent a 'beggy' email but only received a response two weeks after his MP got involved. Mr Ranganathan said: 'I wait two weeks and West Sussex says they've looked in to it they cant do anything. They have conducted an investigation of their placement procedure and they found it to be satisfactory. I bet they have. a 'And then he said to me 'i'm sure it's disappointing'. It's more than disappointing. It's not the football. It's my son's school placement.' Famiies are able to appeal if their child is not offered one of their preferred choices. Mr Ranganathan said they are now on the waiting list and will have their 'fingers crossed'. 'It's school. School's important, isn't it?,' he said. 'Isn't your kids' education... aren't you allowed to be worried about it? Anyway, f***ing annoying.' A council spokesperson told the BBC: 'We don't comment on individual matters, but we acknowledge the disappointment when students cannot be placed at their first choice.' MailOnline has contacted West Sussex County Council for comment. What are the chances of securing a first choice in your area? Use our interactive map below. More than a third of pupils missed out on their first choice secondary school, according to data. Figures released by National Offer Day showed up to 36 per cent missed out in parts of London, while elsewhere in the country it was up to 26 per cent. Experts said in March competition was still fierce for places at the best schools, leading to a high number of rejections. Pepe Di'Iasio, general secretary of the Association of School and College Leaders (ASCL), said: 'Some families will be disappointed. 'The demand for secondary school places has been rising for a number of years and is expected to increase again this year. 'Highly sought-after schools - often in more affluent areas with strong Ofsted ratings - face intense demand, while others struggle with lower pupil numbers, creating financial challenges.'
Associated Press
22-04-2025
- Business
- Associated Press
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities ATLANTA, GA - April 22, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced the appointment of Senthil Ranganathan, Ph.D. as Vice President, Technical Development and CMC Operations. Dr. Ranganathan brings over 20 years of experience in biologics development to commercialization across vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products. This appointment comes at a pivotal time for GeoVax as it advances a comprehensive portfolio of infectious disease vaccines and cancer therapies, positioning the Company to address significant unmet medical needs, contributing to biodefense readiness, and improving vaccine and therapeutic equity through innovation and onshoring. David Dodd, Chairman & CEO of GeoVax, stated: 'We are delighted to welcome Senthil to GeoVax. His track record and expertise in a breadth of biologics development and preparation for registration and subsequent commercialization will support and enhance our progress as we proceed towards the authorization and subsequent commercialization stages for our exciting development portfolio.' Dr. Ranganathan has held senior leadership roles across industry-leading biopharmaceutical companies, most recently serving as Head of Process Development CMC for the Boston site of National Resilience. He previously led global CMC and manufacturing operations at Athersys, Zymeworks, and Alder Biopharmaceuticals (acquired by Lundbeck Biopharmaceuticals). His career has spanned the development and validation of cell and gene therapies, vaccines, bispecific antibodies, and other biologics—from pre-IND through licensure and commercialization. He holds a Ph.D. in Biochemistry from Loyola University Chicago and has authored numerous regulatory submissions and publications in support of breakthrough vaccines, biologics, and therapies. 'I am honored to join GeoVax during such a critical stage of the Company's growth and development,' said Dr. Ranganathan. 'I look forward to working with the outstanding GeoVax team as we develop and execute the roadmap that will bring the GeoVax portfolio to benefit patients and communities worldwide.' About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 View the original release on
Yahoo
19-04-2025
- Politics
- Yahoo
Ranganathan critical after son's school placing
The comedian Romesh Ranganathan has hit out at West Sussex County Council after his youngest son did not get offered any of his preferred choices in his secondary school placement. Mr Ranganathan said he had emailed the council six times after his son was placed in a school "on the other side of town", and not at the same school as his elder brother. He said he had not had a response from the council so he had contacted his local MP, who told him they would look into it, but he was told "they can't do anything about it". A council spokesperson said: "We don't comment on individual matters, but we acknowledge the disappointment when students cannot be placed at their first choice." Mr Ranganathan, who hosts A League of Their Own and a Saturday morning show on BBC Radio 2, said he was particularly angry as his elder son was already at the school the family had selected as his youngest son's first choice. Taking to social media, he said: "It's more than disappointing." He said he had emailed the council six times but had had no response. On taking his case to his MP, Mr Ranganathan said: "I wait two week, they come back and say 'West Sussex has looked into it. They can't do anything. They have conducted an investigation into their placement procedure and found it satisfactory'." "I bet they have," Mr Ranganathan said. "It's not the football, it's my son's school placement. "We have to go on the waiting list and see what happens." The council spokesperson said: "We will always work with families to ensure a suitable school placement can be found." On Wednesday, the council said 91.1% had been offered their first preference school and 98.6% of all applicants were offered a place at one of their three preferences. Follow BBC Sussex on Facebook, on X, and on Instagram. Send your story ideas to southeasttoday@ or WhatsApp us on 08081 002250. School admissions changes to go before councillors Proposed changes to school admissions approved West Sussex County Council
